Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses how to determine which patient with prostate cancer is a candidate for docetaxel versus abiraterone acetate (Zytiga) and prednisone.
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma.
Shane A. Meehan, MD, associate professor, Ronald O. Perelman Department of Dermatology, associate professor, Department of Pathology, director of the Dermatopathology Fellowship Training Program, and director of the Dermatopathology Section at New York University Langone Medical Center, discusses the importance of immunohistochemistry (IHC) testing in melanoma.
Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.
Russell Berman, MD, division chief of Surgical Oncology at NYU Langone Medical Center, NYU Langone School of Medicine, shares insight on the evolving role of surgery in patients with melanoma.
Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.
Richard L. Shapiro, MD, associate professor, Department of Surgery, New York University Langone Medical Center, discusses recent advancements related to surgery in the field of melanoma.
Paul A. Bunn, MD, distinguished professor, Division of Medical Oncology, and James Dudley Chair in Lung Cancer Research, University of Colorado, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.
Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the future of MRI in prostate cancer.
Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.
Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.
Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.
Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the synergy between immunotherapy agents and VEGF inhibitors in renal cell carcinoma (RCC).
Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses selecting a second-line and beyond immunotherapy treatment for patients with bladder cancer.
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer-directed therapy in head and neck cancer.
Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the LATITUDE study in metastatic prostate cancer.
Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the role of interleukin-2 (IL-2) going forward in patients with renal cell carcinoma (RCC).
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses some of the emerging developments on the horizon in mantle cell lymphoma (MCL).
Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.
Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.
Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.
Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.
Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck cancer.
